fashion -WSS

fashion

author：hotspot 2025-10-01 11:46:17 - browse：1921

a doctor wraps a smart watch around a patient's wrist — Adobe

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials. Called Atlas, the platform is designed so that a trial sponsor can research what tools are available to measure things like physical activity or sleep for many commonly studied diseases. CEO Andy Coravos said that robust intelligence can help developers move more quickly and avoid mistakes that require costly changes to trial protocols.

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services. As of 2021, HumanFirst had raised $15 million in venture capital funding, and the decision to sell to Icon for an undisclosed amount comes as some big drug companies are reevaluating their approach to digital technologies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Cognito secures funding to test medical device for Alzheimer's

WSS

NYU radiologists take on the challenge of expensive MRI machines

ARCH Venture Partners is raising $3 billion for a life sciences fund

Anthos stroke drug appears safer than common blood thinner

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

What we need to know about Arena Bioworks

Vertigo drug brings hope for rare neuron disorder, Niemann

explore

fashion

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Astellas still sees hope in its gene therapy after four deaths

Alkermes shareholders re

Readout LOUD podcast: A CRISPR milestone, biotech mixology

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Juul spent big to court Black leaders to promote its e

ChatGPT in medicine: STAT answers readers' burning questions

Vertigo drug brings hope for rare neuron disorder, Niemann

Virginia high school admissions case could be legal follow

Time to name cancers by genetics, not organ of origin, expert says

hotspot

David Sabatini, ex

World's first CRISPR

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Even great ERs can’t make up for American health disparities

Vertigo drug brings hope for rare neuron disorder, Niemann

Biden administration opens offers in Medicare drug price negotiations

entertainment

leisure time

knowledge

hotspot